EverSource Wealth Advisors LLC Has $141,000 Holdings in Sanofi (NASDAQ:SNY)

EverSource Wealth Advisors LLC lowered its position in Sanofi (NASDAQ:SNY) by 29.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,917 shares of the company’s stock after selling 1,227 shares during the period. EverSource Wealth Advisors LLC’s holdings in Sanofi were worth $141,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Synergy Asset Management LLC bought a new position in Sanofi during the fourth quarter worth $25,000. McClarren Financial Advisors Inc. grew its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the period. Sunbelt Securities Inc. raised its position in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares in the last quarter. Sierra Ocean LLC acquired a new position in shares of Sanofi in the 4th quarter valued at about $44,000. Finally, Versant Capital Management Inc bought a new stake in shares of Sanofi during the 4th quarter valued at about $54,000. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Up 2.0 %

Shares of Sanofi stock opened at $58.92 on Tuesday. The stock has a market capitalization of $149.53 billion, a PE ratio of 23.66, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The stock has a 50 day moving average price of $53.85 and a two-hundred day moving average price of $52.83. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on SNY. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.